Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Extended-Release Oral Minoxidil Shows Rapid Onset Of Hair Growth In Female Androgenetic Alopecia
3
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
4
Expanding Oral JAK Inhibitor Options for Children With AD and Alopecia Areata
5